General Archives - Cartherics

Cartherics shares iPSC manufacturing insights at leading cell therapy conferences

Cartherics shares iPSC manufacturing insights at leading cell therapy conferences

Cartherics recently presented at two leading cell therapy conferences in Boston, sharing insights into the development and manufacture of scalable, off-the-shelf CAR-NK therapies.

At the 6th Annual iPSC Summit, Cartherics’ Head of Clinical Manufacturing, Dr Damien Zanker, presented ‘Manufacturing iPSC Therapies at Scale: Advancing Off-the-Shelf CAR-NK Production’ on 10 September.

The presentation highlighted Cartherics’ approach to building […]

Christine Filippis2026-09-24T05:54:44+10:00September 23rd, 2026|Conferences General|

The Research Economy: Australia’s Untapped Gold Mine

The Research Economy: Australia’s Untapped Gold Mine

By Senator Michelle Ananda-Rajah, Senator for Victoria

In an article in the August issue of Inspire, Senator Michelle Ananda-Rajah highlights that Australia’s world-class research sector is an untapped economic opportunity, particularly in health and medical science. Building on the Ambitious Australia report and the Government’s Future Made in Australia agenda, she outlines how Australia can […]

Christine Filippis2026-09-17T07:47:35+10:00September 17th, 2026|General|

Cartherics and Zucker Institute execute research collaboration and option agreement to combine iPSC-derived NK cell platform with novel anti-tissue factor antibody

Cartherics and Zucker Institute execute research collaboration and option agreement to combine iPSC-derived NK cell platform with novel anti-tissue factor antibody

Melbourne, Australia, 1 September 2026 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced that it has executed a research collaboration and option agreement with the Zucker Institute (the commercialisation entity for […]

Christine Filippis2026-09-01T15:17:22+10:00September 1st, 2026|General The Pipeline|

Cartherics welcomes Senator Michelle Ananda-Rajah to its facility

Cartherics welcomes Senator Michelle Ananda-Rajah to its facility

Cartherics was delighted to welcome Dr Michelle Ananda-Rajah to its facility for a tour of the company’s research, development and GMP-ready manufacturing facilities.

The visit provided an opportunity to showcase how Cartherics is advancing the development of off-the-shelf induced pluripotent stem cell (iPSC)-derived CAR-NK cell therapies for high-impact women’s diseases, including ovarian cancer and endometriosis, while […]

Christine Filippis2026-08-27T15:28:32+10:00July 26th, 2026|General|

Cartherics recognised as Asia Pacific Emerging Leader in Allogeneic Cell Therapy

Cartherics recognised as Asia Pacific Emerging Leader in Allogeneic Cell Therapy

Melbourne, Australia, 1 July 2026 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026.

Cartherics is emerging as a […]

Christine Filippis2026-07-01T15:13:31+10:00July 1st, 2026|General|

Cartherics strengthens global IP portfolio with Japanese patent grant

Cartherics strengthens global IP portfolio with Japanese patent grant

Melbourne, Australia, 10 June 2026 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce the issuance of a patent for “Genetically modified cells and uses thereof” by the Japanese Patent Office.

This is the second granted patent in Japan […]

Christine Filippis2026-06-10T13:37:11+10:00June 10th, 2026|General The Pipeline|

CAR-NK cell therapies for solid tumours: Closing the gap between perception and reality

CAR-NK cell therapies for solid tumours: Closing the gap between perception and reality

By Drs Ian Nisbet & Walid Azar

As published in Pharmaphorum – 14 May 2026

Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to solid tumours, perceptions about their effectiveness often lag behind the emerging scientific evidence.

In particular, Chimeric Antigen Receptor – Natural Killer (CAR-NK) […]

Christine Filippis2026-05-14T11:12:41+10:00May 14th, 2026|General The Pipeline|

World Ovarian Cancer Day Q&A: Heather Hawkins on symptoms, survival and progress

World Ovarian Cancer Day Q&A: Heather Hawkins on symptoms, survival and progress

Today on World Ovarian Cancer Day, we pause to listen, reflect, and amplify the voices of those who have experienced ovarian cancer first-hand. At Cartherics, this day is a powerful reminder of why we do what we do – driving awareness and advancing new treatment options that offer real hope for women.

We’re honoured to share […]

Christine Filippis2026-05-08T09:31:23+10:00May 8th, 2026|General|

Cartherics and Catalent Expand Commercial License Agreement

Cartherics and Catalent Expand Commercial License Agreement

April 9 (US ET), 2026 – Melbourne, Australia, and Tampa, FL – Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership.

The companies […]

Christine Filippis2026-04-10T07:59:09+10:00April 10th, 2026|General The Pipeline|

Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

By Wholesale Investor

In the high-octane world of biotechnology, success is often measured by the narrowest of margins. But for Dr. Ian Nisbet, CEO of Melbourne-based Cartherics Pty Ltd, the mission is defined by a gap so large it has become a “tragic” outlier in modern medicine: the chronic underfunding of women’s health.

Ovarian cancer, often called […]

Christine Filippis2026-04-08T11:13:36+10:00April 8th, 2026|Conferences General Investor News|

General

About us

Sign up to our newsletter